Translation of "Solide tumore" in English

This is also valid for radiation-induced leukemia and solid cancers.

Entirely different is the latency distribution for solid cancers.

Most aggressive second primary tumors are malignant solid tumors.

Solid tumours may precede, occur concurrently or follow the diagnosis of LCH.

In November 2010, the US FDA approved denosumab (to be marketed as "Xgeva") for the prevention of skeletal-related events in patients with bone metastasis from solid tumors.

Except for haematological and hepatic events (see below), generally the frequency and severity of undesirable effects in AIDS-KS patients were similar to those noted in patients with other solid tumours treated with paclitaxel monotherapy.

Binocrit is used to treat anaemia in adults receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma (bone marrow cancer) who may have a need for a blood transfusion.

The incidence rates per 100 patient-years were 0.73 for non-melanomatous skin cancer, 0.59 for solid malignancies and 0.13 for hematologic malignancies.

The main measure of effectiveness was the proportion of patients who responded to treatment (objective response rate) and whose tumour shrank, which was assessed using body scans and standardised criteria for solid tumours.

Solid tumours were reported in 2.5% and 1.9% of Empliciti combined with lenalidomide and dexamethasone and lenalidomide and dexamethasone treated patients, respectively.

Binocrit is used to treat anaemia in adults receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma (bone marrow cancer) who may have a need for a blood transfusion.

Solid tumors need sufficient blood supply, thus secreting growth factors that initiate the formation of new blood vessels in tumor tissue.

The new estimates yield for the considered exposure conditions a risk value for the total number of malignancies (leukemia -t· solid cancers) which is about a factor 2 - ƒ higher than the estimate of UNSCEAR ten years ago.

The data available up to now enable, therefore, no direct conclusion on the final lifetime risk of radiogenic solid cancers.

Proceeding from the present excess rate of solid cancers, UNSCEAR (1977) has estimated a final value of 4 - 6 for this ratio, applying a so-called "absolute" risk projection model.

The main reason for the higher new values is not the revised dosimetry but the application of a relative risk projection model for solid cancers assuming a constant relative excess risk with time after exposure.

As it follows from the above-given test results, compound (IV) combines in itself the best property of 5-fluorouracyl--its high antileukemic activity with the best properties of Ftorafur--its low toxicity and a high antitumor activity in respect of solid tumors.

The next generation of nanoparticles provide for temperature-dependent drug release and will significantly accelerate the expansion of the treatment for other solid tumors such as Esophageal and Pancreatic Cancers.

Our work covers fields with high medical expectations: solid tumors (breast, lung, colon, ovarian, bladder and ENT cancers), liquid tumors (leukemia, myeloma, bone marrow transplant) and onco-dermatology. Â

By enabling doctors to treat solid tumors directly with minimal impact on surrounding tissue, the treatment is expected to reduce the tissue damage, compared to current radiation treatments.

Cesium-137 can cause solid tumors and genetic defects in offspring when inhaled or ingested through food or water, while strontium-90 is a known cause for leukemia.

Solid tumors form shortly afterward, affecting the breast muscle, kidneys, and spleen, among other areas.

As from a specific size, solid tumors form a capillary network of blood vessels that grows along with them.

Solid tumors are preferred, particularly local and locally advanced tumors, or systemic tumor diseases, which cause local problems such as inoperable metastases.

The compounds according to the invention are suitable for prophylaxis and/or treatment of hyperproliferative disorders, for example psoriasis, keloids and other hyperplasias which affect the skin, benign prostate hyperplasias (BPH), solid tumours and haematological tumours.

Solid tumours that can be treated in accordance with the invention are, for example, tumours of the breast, the respiratory tract, the brain, the reproductive organs, the gastrointestinal tract, the urogenital tract, the eye, the liver, the skin, the head and the neck, the thyroid gland, the parathyroid gland, the bones, and the connective tissue and metastases of these tumours.

Examples can be found in tumorous diseases, joint diseases and vascular diseases, and in particular with solid tumours and arterial vascular diseases.

Our research at the Department of Pediatric Oncology, Hematology, Immunology and Pulmonology has two main focal areas: pediatric oncology, hematology and immunology (leukemias and solid tumors, benign blood disorders, disorders of the iron metabolism, congenital immunodeficiencies) and pediatric pulmonology, allergology and cystic fibrosis (severe lung diseases like cystic fibrosis and allergic diseases).

Medigene will now evaluate preclinically the use of this chimeric co-stimulatory receptor in combination with tumor-specific TCR-Ts generated by Medigene to potentiate immune responses against solid tumors.